Key Highlights

Risk & Performance

Pipeline Risk Assessment

Based on historical performance

High Risk

Score: 60/100

Failure Rate

6.0%

5 terminated/withdrawn out of 84 trials

Success Rate

58.3%

-28.2% vs industry average

Late-Stage Pipeline

25%

21 trials in Phase 3/4

Results Transparency

14%

1 of 7 completed trials have results

Key Signals

14 recruiting1 with results

Enrollment Performance

Analytics

Phase 1

35(42.2%)

Phase 2

25(30.1%)

Phase 3

19(22.9%)

Phase 4

2(2.4%)

N/A

2(2.4%)

83Total

Phase 1(35)

Phase 2(25)

Phase 3(19)

Phase 4(2)

+1 more

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (84)

Showing 20 of 84 trials

NCT07665970Phase 1Not Yet Recruiting

SCTB41 Plus SCTB39G With or Without Standard Therapy in Advanced Solid Tumors

Role: lead

NCT07662395Phase 2Recruiting

SCTB41 Combined With Chemotherapy in Advanced Squamous Non-Small Cell Lung Cancer

Role: lead

NCT07609251Phase 2Not Yet Recruiting

A Clinical Study of SCTB41 Combined With Docetaxel in Patients With Previously Treated Locally Advanced or Metastatic Non-Small Cell Lung Cancer（Phase II Study Ongoing）

Role: lead

NCT07594028Phase 1Not Yet Recruiting

Phase I/II Study of SCTB41 Plus SCTB39-1with or Without Standard Therapy in Advanced Solid Tumours

Role: lead

NCT07570823Phase 3Not Yet Recruiting

A Study to Evaluate the Safety and Efficacy of SCTB35 in Combination With Gemcitabine and Oxaliplatin in Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma

Role: lead

NCT07040072Phase 1Recruiting

Finotonlimab Combined With Stapokibart in the Treatment of Recurrent/Metastatic HNSCC

Role: collaborator

NCT07562022Phase 3Not Yet Recruiting

A Study to Evaluate the Safety and Efficacy of SCTB35 in Combination With Lenalidomide in Patients With Relapsed or Refractory Follicular Lymphoma

Role: lead

NCT07244510Phase 2Recruiting

Efficacy and Safety of SCT650C in Participants With Moderate to Severe Hidradenitis Suppurativa

Role: lead

NCT07538154Phase 1Not Yet Recruiting

A Clinica Study of SCTC21C in Participants With Systemic Lupus Erythematosus

Role: lead

NCT07437404Phase 3Recruiting

Efficacy and Safety Evaluation Study of SCT800 in Previously Untreated Hemophilia A Patients.

Role: lead

NCT07388810Not ApplicableNot Yet Recruiting

Study of Ripertamab in Children With Frequent Relapses or Steroid-Dependent Nephrotic Syndrome

Role: collaborator

NCT07388602Phase 3Recruiting

A Study to Evaluate the Safety and Efficacy of SCTC21C in Combination With Bortezomib, Cyclophosphamide, and Dexamethasone in Patients With Newly Diagnosed Systemic Light-Chain Amyloidosis (NDSLCA)

Role: lead

NCT07297329Phase 3Recruiting

A Study to Evaluate the Safety and Efficacy of SCTC21C in Combination With Bortezomib, Lenalidomide and Dexamethasone in Patients With Newly Diagnosed Multiple Myeloma Not Eligible for Transplant

Role: lead

NCT07362459Phase 3Recruiting

A Study to Evaluate the Safety and Tolerability of SCTB14 as First-Line Therapy in Non-Small Cell Lung Cancer.

Role: lead

NCT04644185Phase 2Terminated

The Efficacy and Safety of SCTA01 in Hospitalized Patients With Severe COVID-19

Role: lead

NCT06672536Phase 1Recruiting

Multicenter, Phase I/II Study to Evaluate the Safety, Tolerability, PK and Efficacy of SCT520FF in Patients With nAMD

Role: lead

NCT07077252Phase 1Not Yet Recruiting

Phase I/II Study of SCTB39G in Advanced Solid Tumours